Kornimate/medical-research-clean huggingface dataset:
pediatric perioperative satisfaction questionnaire

Conditions: Perioperative; Children; Satisfaction

Summary: the aim of this study is to develop and validate a self-report questionnaire to evalutate the satisfaction of the children after surgery.

step 1 : development of the questiontionnaire face to face interview to report the satisfaction of the children after surgery and to identify recurrent themes to generate questions. step 2 : validation of the questionnaire evaluation of the psychometric validity of the final questionnaire

Eligibility criteria:
inclusion criteria: * children 7 years and older * elective surgery * general anesthesia * abiliy to understand and read questions exclusion criteria: * emergency * cognitive trouble * intellectual disability

Keywords: validity questionnaire children health quality of life self report
finite element and z shap mini plate with lingual extension

Conditions: Mandible Fracture

Summary: * a cone beam ct (cbct) scan of the patient, will be used to create a 3d scanned image of parasympheseal mandibular fracture * 3d images will be introduced to finite element (fa)software to evaluate stresses (mpa) and life time (cycle) for each model and determine which plate is the best


Eligibility criteria:
inclusion criteria: - parasymhyseal fracture exclusion criteria: • absence of other facial trauma, mandibular condylar fracture
a regulatory requirement post-marketing surveillance study to monitor the safety and efficacy of twynsta (telmisartan + amlodipine spc, q.d.) in korean hypertensive patients requiring combination therapy

Conditions: Hypertension

Summary: this is a prospective, observational, open-label, multi-center study, which will provide detailed information about the safety and efficacy of twynsta tablets in korean hypertensive patients requiring combination therapy. this will present a convenient treatment option for hypertension in korean patients.

study design: pms observational study

Eligibility criteria:
inclusion criteria: no specific inclusion and exclusion criteria will be provided due to the exploratory character of the study. patients who have initiated twynsta tablets according to the recommended and approved usage in korea will be consecutively enrolled. exclusion criteria: no specific inclusion and exclusion criteria will be provided due to the exploratory character of the study. patients who have initiated twynsta tablets according to the recommended and approved usage in korea will be consecutively enrolled.
a phase iii study to evaluate the efficacy and safety of ak120 in patients with moderate to severe atopic dermatitis

Conditions: Atopic Dermatitis

Summary: this is a randomized double-blind, placebo-controlled, multicenter phase iii clinical study evaluating the efficacy and safety of ak120 injection in the treatment of patients with moderate to severe atopic dermatitis.

this is a randomized double-blind, placebo-controlled, multicenter phase iii clinical study evaluating the efficacy and safety of ak120 injection in the treatment of patients with moderate to severe atopic dermatitis. the entire study included a screening period, a double-blind controlled treatment period, a conversion and maintenance treatment period, and a safe follow-up period.

Eligibility criteria:
inclusion criteria: 1. male or female subjects aged ≥18≤75 years old. 2. atopic dermatitis (ad) diagnosed at least 1 year before screening. 3. subject with eczema area and severity index (easi) score ≥16, investigator global assessment (iga) score≥ 3, body surface area (bsa) score ≥ 10% at screening and baseline. 4. previously received at least 4 weeks of moderate to strong or at least 2 weeks of strong local glucocorticoid (tcs) treatment for ad before screening, with poor efficacy or intolerable exclusion criteria: 1. acute onset of ad within the first 4 weeks of randomization. 2. have participated in any clinical research on ak120 in the past 3. received systemic corticosteroids, immunosuppressive/immunomodulatory drugs, phototherapy within the 4 weeks before randomization. 4. received treatment with other clinical research drugs (non-biological agents) within the first 4 weeks or 5 half-lives of randomization (whichever is longer) 5. received or planned to receive live vaccine treatment within the 3 months before randomization or during the study period. 6. received allergen specific immunotherapy within the 3 months before randomization. 7. have a history of allergies to any component of ak120 and/or severe allergic reactions to monoclonal antibodies.
validation of structured light plethysmography - health and disease

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Summary: validation of structured light plethysmography (slp) in patients with conditions such as chronic obstructive pulmonary disease (copd) that effect breathing and in healthy participants.

the investigators hypothesize that slp may be a useful tool to differentiate between different respiratory diseases. to further examine differences in disease and health, and between diseases slp measurements will be recorded in a range of diagnostic conditions that effect breathing and in healthy normal subjects. this is a non-randomised observational study to validate structured light plethysmography in two groups of participants: those with respiratory condition such as copd and a normal healthy group. neither group will receive any clinical intervention. slp data capture and spirometry (as part of the patients clinical care) will be performed by the patients. the data collected from this study will allow examination of different breathing patterns between patients with different diseases, to compare breathing patterns in patients to those in healthy individuals, and to compare breathing patterns within a healthy population.

Eligibility criteria:
inclusion criteria: * aged between 0 and 80 years exclusion criteria: * any contraindication to spirometry (if performed) or a history of a myocardial infarction or chest surgery within 4 weeks * patient unable to sit in an upright (or supine in the case of infants) position for required period of time * patients with significant co morbidities (assessed by the clinician at screening only): * chest wall or spinal deformity e.g. scoliosis * obstructive sleep apnoea (osa) apnoea hypopnoea index \> 30 (if known) * an acute or chronic condition that, in the investigator's opinion, would limit the patient's ability to participate in the study * bmi \> 40 * inability to consent/comply with trial protocol
fiberoptic bronchoscopy and bronchoalveolar lavage in critically ill ventilated patients

Conditions: Fiberoptic Bronchoscopy (FOB); Bronchoalveolar Lavage (BAL); Respiratory Disease

Summary: fiberoptic bronchoscopy (fob) is widely used as a diagnostic or therapeutic procedure in intensive care units. patients with ards or covid-19 disease often undergoes to these procedures. however, intensive care patients might suffer from serious side effects such as prolonged oxygen desaturation and adverse change in lung compliance and resistance. this study aims to evaluate these changes and determine their impact on patient stability.

fiberoptic bronchoscopy (fob) is widely used in intensive care units as a diagnostic or therapeutic procedure. fob in respiratory failure patients supported by mechanical ventilation may worsen hypoxemia and hypercapnia, therefore fob requires careful consideration in this patient population. the generally accepted indications for fob in ventilated patients are removal of retained secretions, resolution of atelectasis and evaluation of hemoptysis. a diagnostic indication is the bronchoalveolar lavage (bal), to sample the lower respiratory tract without contamination. studies of fob performed in mechanically ventilated patients suggest an acceptable safety profile, except for the occurrence of hypoxemia as the main adverse event. bronchoalveolar lavage (bal) in normal volunteers is reported to be safe and does not lead to measurable changes in pulmonary function parameters. however, in intensive care patients may suffer from serious side effects such as prolonged oxygen desaturation. moreover, reductions in arterial oxygen tension (pao2) have been reported to persist in some patients for 4 h and more after the procedure. authors reported the bal procedure is associated to a worsening of pao2/fio2 ratio, in several ards patients the drop in pao2 was higher than 30%. moreover a physiological study in patients undergoing fob and bal showed adverse change in lung compliance and resistance. the purpose of this prospective study is to determine the alterations in respiratory mechanics (regional compliance and resistance) and gas exchange induced by fob and bal up to 6 hours after the procedure. the lung regional ventilation evaluation will be made by electrical impedance tomography (eit).

Eligibility criteria:
inclusion criteria: mechanically ventilated icu patients requiring a fob or fob + bal exclusion criteria: * pao2/fio2 ratio \<100 * age \< 18 years * pregnancy * unstable angina and recent (less than 1 week) myocardial infarction * uncontrolled cranial hypertension * major hemodynamic instability * any previous lung surgery (except for lung transplantation) * obesity (bmi \> 50) * chest circumference \> 150 cm * electronic implanted device (pacemaker, neurostimulator, etc.) patients who had undergone several bronchoscopy procedures could not be included twice.

Keywords: respiratory insufficiency respiratory distress syndrome mechanical ventilation covid-19 fiberoptic bronchoscopy (fob) bronchoalveolar lavage (bal)
metastatic breast cancer in brazil: characterization of patients and treatments

Conditions: Metastatic Breast Cancer

Summary: the purpose of this study is to describe demographics and socioeconomics characteristics associated to the diagnosis of metastatic breast cancer in brazil.

the primary aim of this study is to characterize patients and treatments of metastatic breast cancer in brazil. other specific aims are: * to describe patients demographics and socioeconomic characteristics * to describe the bc pathological characterization * to describe treatment (describe each treatment with dates start-end, cycles, dosing, sequence and line of treatment, reason for discontinuation) * to analyze patients outcome (time to progression, site of metastasis, progression free survival (pfs), overall survival (os), skeletal related events (sre))

Eligibility criteria:
inclusion criteria: * women \> 18 years old * patients diagnosed with de novo or recurrent metastatic breast cancer during the period of january to december 2012 * any invasive breast cancer histology and subtype exclusion criteria: * male breast cancer

Keywords: breast cancer metastasis
low sodium diet in oligohydramnios assigned for conservative management

Conditions: Oligohydramnios

Summary: the investigators want to examine whether low salt diet can increase the amniotic fluid index in patients diagnosed with oligohydramnios and assigned for conservative management. a randomized controlled trial

few studies have addressed the changes in maternal diet as affecting the composition and amount of amniotic fluid. some articles have shown an increase in amniotic fluid volume as a result of maternal hydration during pregnancy through intravenous fluid infusions and oral fluid intake, the increase was evident in women with amniotic fluid and women with normal amniotic fluid volume. in a mechanism similar to that of liquid hydration, a low-salt diet may lead to an increase in the volume of amniotic fluid. the investigators would like to examine whether a low-salt diet in women with amniotic fluid is able to significantly increase the amount of amniotic fluid compared with a regular diet.

Eligibility criteria:
inclusion criteria: * pregnant women between 24-37 weeks of gestation, single fetus, who were diagnosed with an amniotic fluid index at the 5th percentile or below, according to the current gestational age * no medical indication for immediate delivery exclusion criteria: * refusal to participate in the study * a medical recommendation for delivery within two weeks of diagnosis * fetal malformation or proof of fetal infection that known to cause oligohydramnios (eg cmv). * premature rupture of membrane * multiple pregnancy * medical contraindication to the low-salt diet

Keywords: oligohydroamnios low salt diet
neck strengthening program for the prevention or mitigation of sports concussion

Conditions: Concussion, Brain

Summary: study looks to determine effectiveness of neck strengthening to reduce the incident, duration, and severity of sports related concussion in student athletes.

after recruitment, subjects will have neck strength measured as baseline in addition to doing scat5 for baseline and eye tracking, funding pending, in order to compare later assessment for concussion. throughout study, subject will perform basic, unweighted and weighted neck strengthening exercises twice a week. periodic re evaluations of neck strength will be performed in order to determine progress. any time a subject incurs a sports related concussion, a scat5 assessment, and eye tracking funding pending, will be done and compared to baseline to measure severity of injury. weekly follow ups will be done to assess duration of concussion. all measurements, assessments, and exercises are non-invasive and provide minimal risk to subjects.

Eligibility criteria:
inclusion criteria: * involved in programmatic athletic activities with an ongoing duration of at least 4 weeks. * written informed consent obtained by the subject or subject's legal guardian. * written assent from subjects ages 8 years old and above * subject is between the ages of 5 and 22 years, male or female. * subjects from all racial and ethnic origins will have an opportunity to participate. exclusion criteria: - corrected vision less than 20/500.

Keywords: concussion football student athlete sports
soluble st2 in patients with heart failure"

Conditions: Heart Failure Patients

Summary: 1. the aim of this study was to explore the relationship between peripheral circulating serum soluble suppression of tumorigenicity-2 (sst2) levels and inflammatory biomarkers in patients with heart failure 2. additive role of sst2 to nps in of heart failure patients

heart failure (hf), a complex and heterogeneous medical syndrome characterized by structural and functional cardiac abnormalities and hemodynamic disruptions, represents the end-stage manifestation of numerous cardiovascular disorders . hf is categorized into three groups based on the measurement of the left ventricular (lv) ejection fraction (lvef) according to the european society of cardiology (esc) guidelines issued in 2021: hf with reduced ejection fraction (hfref, lvef ≤ 40%), hf with mildly reduced ejection fraction (hfmref, lvef 41-49%), and hf with preserved ejection fraction (hfpef, lvef ≥ 50%) . quantifying concentrations of circulating biomarkers plays a major role in most cardiovascular (cv) diseases, including (hf) . an ideal biomarker in hf should be measured non-invasively and at low cost, highly sensitive to allow for the early detection of the disease . n-terminal pro-b-type natriuretic peptide (nt-probnp) released by cardiac muscle tissue in response to abnormal volume load is an established indicator for the diagnosis and prognosis of hf . however, there are important limitations to natriuretic peptide (np) testing in hf . soluble suppression of tumorigenicity-2 (sst2) is the circulating form of the interleukin-33 membrane receptor released in response to inflammation, fibrosis in various organs, and myocardium stress . soluble (s)st2 has been proposed as a useful biomarker for heart failure (hf) patient management. myocardial damage or mechanical stress stimulate sst2 release. st2 competes with a membrane bound receptor (st2 ligand, or st2l) for interleukin-33 (il-33) binding, inhibiting the effects induced by the st2l/il-33 interaction so that excessive sst2 may contribute to myocardial fibrosis and ventricular remodelling. so biomarkers such as nt-probnp and sst2 could potentially be used as surrogates for clinical outcomes in patients with hf and may be useful in monitoring disease progression and assessing the response to therapy .

Eligibility criteria:
inclusion criteria: * patients 18-80 years. * both sexes will be included. * including signs and symptoms of hf (e.g., elevated jugular venous pressure and altered apical beat position), altered lvef (\< 40%; 40%-49%; ≥ 50%) exclusion criteria: * patients \<18 years * patients with documented evidence of cardiogenic shock . * patients with acute coronary syndrome within 30 days. * chronic kidney disease patients with glomerular filtration rate \< 30 * patients with interstitial pulmonary fibrosis .
mast cells are involved in the mechanism of npsle epilepsy

Conditions: Lupus Erythematosus, Systemic

Summary: tryptase, tlr4, and anti-nr2a antibodies were measured in serum, cerebrospinal fluid, and subjects and other markers to assess their relevance to disease activity, aiming to find new therapeutic targets,timely intervention to improve the prognosis of sle and improve the quality of life of patients with sle.

this study is a prospective cohort study: it is proposed to be divided into 3 groups, namely healthy control group and sle group, npsle epilepsy group; fifteen cases were included in each group, with the consent of the subjects and signed to know consent form, record all subjects' clinical and laboratory test data, and test subjects' blood. markers such as cerebrospinal fluid tryptase, tlr4 and anti-nr2a antibodies, follow-up 2 year, the patient's disease activity is evaluated every year, the change of indicators is dynamically observed, and statistical points are made divide.

Eligibility criteria:
inclusion criteria: 1. healthy control group * voluntary signing of informed consent; * healthy volunteers older than 18 years old and less than 50 years old, regardless of gender; * no systemic diseases or neurological symptoms or signs; * according to the judge's judgment, healthy volunteers matching the npsle epilepsy group in terms of gender, age, and education level were selected as the control group. 2. sle group * voluntary signing of informed consent; * age greater than 18 years old, less than 50 years old, gender is not limited; * patients with sle who meet diagnostic criteria. 3. npsle epilepsy group * voluntary signing of informed consent; * age greater than 18 years old, less than 50 years old, gender is not limited; * patients with npsle epilepsy who meet diagnostic criteria. exclusion criteria: 1. sle group * patients with sle with other autoimmune diseases; * previous seizures, psychiatric abnormalities and other manifestations; * mr of the head has obvious abnormal signals in the skull or eeg shows abnormal signals; * history of use of hormones and immunosuppressants; * the investigators judged that it was not suitable to participate in this study. 2. npsle epilepsy group * prior history of epilepsy or clear cranial mr findings suggesting structural abnormalities; * presence of precipitating seizures such as sleep deprivation, high fever, infection, long-term abstinence from alcoholism * interrupt, patients with systemic diseases such as hypoglycemia, severe electrolyte disorders, malignant lesions, progressive or degenerative diseases, severe liver and kidney insufficiency and other metabolic diseases; * the investigators judged that it was not suitable to participate in this study.
treatment of japanese encephalitis

Conditions: Japanese Encephalitis

Summary: japanese encephalitis is the single largest cause of viral encephalitis in the world today. it occurs in yearly post monsoon outbreaks in uttar pradesh and other parts of india and south east asia. there is presently no antiviral drug of proven benefit for this illness and treatment is mostly supportive. the drug ribavirin is already in the market in use for other indications. it has been found useful in west nile encephalitis and various hemorrhagic fevers caused by related arboviruses. this is a double blind placebo of ribavirin in japanese encephalitis. to the best of our knowledge, this is the first such trial in the world. the study hypothesis is that children treated with ribavirin will be no different from those getting placebo in terms of mortality, length of hospital stay, days to return to consciousness and oral feeds, days to become afebrile and convulsion free and in 3 month sequelae rate.


Eligibility criteria:
inclusion criteria: * child between 6 months and 12 years age * acute febrile encephalopathy * positive igm elisa test for japanese encephalitis in serum exclusion criteria: * consent not obtained
a study of etoricoxib in participants with osteoarthritis not responding to analgesic drugs (mk-0663-142)

Conditions: Osteoarthritis

Summary: this two-part study will evaluate the effectiveness of etoricoxib in controlling pain in participants with osteoarthritis who are experiencing inadequate response to their current treatments. in part 1, all participants will receive open-label etoricoxib 60 mg daily. those participants who experience a clinically meaningful response to etoricoxib 60 mg daily within two weeks will be eligible to enter the double-blind withdrawal period (part ii). responders entering part 2 will be randomized in a 1:1 ratio to receive either etoricoxib 60 mg or placebo.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of osteoarthritis of the knee or hip that requires treatment * american rheumatism association (ara) functional class i, ii or iii * receiving a stable dose of a traditional non-steroidal anti-inflammatory drug (nsaid), a cox-2 selective inhibitor (other than etoricoxib, e.g. celecoxib), opioid therapy or tramadol to treat their osteoarthritis-related pain for at least 2 weeks and willing to maintain treatment during baseline phase * moderate to severe daily pain intensity on his or her current pain regimen * excepting osteoarthritis, patient is judged to be in otherwise general good health based on medical history, physical examination, and routine laboratory tests * negative serum pregnancy test exclusion criteria: * has not experienced at least 3 consecutive days of daily pain intensity \>4 on 10-point scale * severe hepatic insufficiency * advanced renal insufficiency * presence of gastro-intestinal ulcer disease with active bleeding or history of the same within the past 6 months or a presence or history of inflammatory bowel disease * history of gastric, biliary (including gastric bypass surgery), or small intestinal surgery that results in clinical malabsorption * receiving or will likely require treatment with ≥14 consecutive days or repeated courses of pharmacologic doses of corticosteroids * established ischemic heart disease, peripheral arterial disease, and/or cerebrovascular disease including a history of stroke, myocardial infarction or transient ischemic attack, and recent revascularization procedures * any other contraindications mentioned in the approved study drug european union (eu) summary of product characteristics (smpc) * therapy with glucosamine and/or chondroitin sulfate for \<6 months prior to study start.